EP Patent

EP4233837A1 — Solid and oral etoposide toniribate compositions

Assigned to CellAct Pharma GmbH · Expires 2023-08-30 · 3y expired

What this patent protects

The present invention relates to new stable oral pharmaceutical formulations of etoposide toniribate, lyophilized composition of etoposide toniribate solutions and methods of treating cancer using said formulations and compositions.

USPTO Abstract

The present invention relates to new stable oral pharmaceutical formulations of etoposide toniribate, lyophilized composition of etoposide toniribate solutions and methods of treating cancer using said formulations and compositions.

Drugs covered by this patent

melphalan-hydrochloride (MELPHALAN HYDROCHLORIDE)

Patent Metadata

Patent number: EP4233837A1
Jurisdiction: EP
Classification: —
Expires: 2023-08-30
Drug substance claim: No
Drug product claim: No
Assignee: CellAct Pharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.